Modelled projections from observational data suggest greater lowering of Lp(a) concentration may result in larger absolute reductions in recurrent coronary heart disease (CHD) risk than less Lp(a) lowering among adults with established atherosclerotic cardiovascular disease (ASCVD).1
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
